The 2025 GCIG Spring Meeting in Chicago gathered over 170 delegates from all 33 member groups, focusing on pragmatic trials – cost-effective, patient-centred studies applicable in real-world clinical practice, including low-resource settings. The meeting featured impactful plenary sessions, pre-recorded lectures, and interactive brainstorming in disease-specific groups. Discussions covered topics such as:

  • Involving patients from trial design to result dissemination
  • Reducing toxicity without compromising efficacy
  • Innovative approaches like synthetic control arms, dose de-escalation, fertility-sparing approaches, AI modelling, and decentralized trials
  • Designing inclusive protocols with broader eligibility criteria
  • New proposals in ovarian, endometrial, cervical, and rare tumours, as well as symptom benefit research

 

The brainstorming sessions generated 33 trial concepts, of which 15 were discussed in detail. Early Career Investigators played an active role, contributing ideas and collaborating internationally.

CEEGOG was represented by Dr. Zoltán Novák from the National Cancer Institute, Budapest. Our sincere thanks to Dr. Novák for representing our group at this important international meeting.

The next GCIG Autumn Meeting will be held on October 15–16, 2025, in Berlin, Germany.

On May 23, 2025, the annual CEEGOG meeting took place in Prague, bringing together 67 participants representing 41 sites. We thank all who joined and contributed to the discussions.

Key highlights from the meeting:

  • Awards to the 10 most active sites in academic research in 2024 (certificates + ESGO 2026 registration fee covered by CEEGOG).
  • 4 academic trials open for collaboration: MYSTR, CERVANTES, RECER, RACE.
  • Achievements in 2024 & 2025 include initiation of academic and commercial ENGOT studies in multiple CEEGOG countries, SENTIX final outcome accepted for publication in Nature Cancer and CEEGOG joining ENGOT Leadership for 2026–2028.
  • New proposals: 3 prospective studies and 1 survey.
  • Reminder: according to updated CEEGOG Bylaws, sites without research activity will be excluded from the CEEGOG Board.

We thank all CEEGOG members for their continued support and collaboration on CEEGOG/ENGOT/GCIG projects and wish everyone a relaxing and enjoyable summer!

 

Photo Gallery – CEEGOG Annual Meeting 2025
A few moments captured from our annual meeting in Prague. Thank you to everyone who joined and contributed to the success of this year’s event.

 

 

New Publication from CEEGOG CX-07 / RECER Study

We are pleased to announce the publication of a new article related to the CEEGOG CX-07/RECER study in the International Journal of Gynecological Cancer.

The RECER study aims to evaluate the risk factors associated with the regression or persistence of high-grade cervical lesions (HG lesions).

We also remind our members and collaborators that there is still an opportunity to participate in this ongoing academic CEEGOG study. If you are interested in joining or would like to receive more information, please feel free to contact the CEEGOG office.

We sincerely thank all participating sites for their continued support and collaboration.

📄 Read the article here: https://www.international-journal-of-gynecological-cancer.com/article/S1048-891X(25)00885-0/fulltext

The latest ENGOT meeting, held on April 3-4, 2025, gathered representatives from all ENGOT groups to review progress across numerous ongoing and completed trials, present updates from working groups, and discuss strategic priorities.

CEEGOG was represented by its Chair Prof. David Cibula and Administrative Manager Mrs. Ivana Nohová. From the CEEGOG studies, updates on the SENTIX and CERVANTES were presented.

Highlights included:

  • Clinical Trials – Updates on recruitment, regulatory progress, and key milestones across multiple ENGOT model A, B, and C studies in ovarian, endometrial, and cervical cancer s well as an overview of new proposals, including all GCA 2024 trial proposals.
  • Scientific Achievements – Several trials are nearing completion, with data expected to be presented at major conferences such as ESGO, ESMO, and ASCO in 2025–2026.
  • Working Group Reports – Operational updates, improved templates for contracts and trial budgeting, and new guidelines for ENGOT presentations to pharmaceutical companies.
  • Strategic Discussions – Strengthening academic trial support, refining publication rules, ensuring representation in trial steering committees, and planning for future leadership rotations.
  • Collaborative Initiatives – Expansion of the Rare Tumour Registry, TR group biobank projects, and ESGO database.

CEEGOG is now a full partner in most clinical trials which influence the standard of care. We thank all participating sites for their interest in offering new treatment options to their patients and for their commitment to clinical research as a whole.

We are pleased to invite you to the State-of-the-Art Conference on Gynecology and Oncology, a brand-new type of meeting organized by the Central and Eastern European Gynecologic Oncology Group (CEEGOG). The conference will take place on September 29–30, 2025, in Prague, and will offer not only an excellent educational programme but also a unique opportunity to showcase the dynamic Central and Eastern European region.

The conference will provide a comprehensive overview of the latest recommendations across the entire field – from diagnosis and surgical treatment to systemic therapies and palliative care. Most of the speakers will come from our region east of the German border, offering valuable regional insights.

More information is available on the conference website: www.sago-conference.eu

We look forward to welcoming you all to Prague in September 2025! 

 

We are pleased to invite you to  the next year’s Annual Meeting of our Collaborative Group CEEGOG, which will take place on Friday, May 23, 2025, at the Department of Gynecology, Obstetrics, and Neonatology of the General University Hospital in Prague.

We look forward to the opportunity to meet you all in Prague and kindly ask you to save the date of 23 May 2025. Thank you in advance.

 

The GCIG Fall Meeting was held virtually in split sessions on November 18, November 21, and December 6, 2024. The meeting was shortened, and focused mainly on the concepts of pragmatic trials. Discussions emphasized the urgent need for practical, affordable, and practice-changing real-world clinical trials designed to produce results applicable to the general population rather than idealized patient cohorts. The value of real-world data, routinely collected from diverse sources outside traditional clinical research settings, was underscored.

Several ideas for pragmatic trials were introduced as well. Efforts should focus on collecting only essential patient data for analysis, reducing the volume of the data gathered, and on streamlining research processes. The key research questions include determining the optimal duration of CPi and PARPi treatment, exploring treatment sequencing, and evaluating strategies for treatment de-escalation. A persistent challenge remains that many novel therapeutics, while impactful in driving global practice changes, are unlikely to be accessible across all clinical settings and countries.

The GCIG's vision of ending gynecologic cancer through global, collaborative research must continue to guide these efforts.

The ENGOT GCA workshop held in 13-15 November 2024 in Stresa Italy, was a dynamic and inspiring event that showcased the latest advancements in GO. We enjoyed a series of thought-provoking presentations and interactive discussions, promoting collaboration and sharing best practices. The atmosphere was filled with enthusiasm and a shared vision for the future, leaving me motivated and ready to implement new ideas in my work concerning the interests of patients and CEEGOG. Many thanks. MIHAI STANCA, MD, PhD, Târgu Mureş, Romania

Amazing meeting with old friends, exchanging knowledge, skills and expertise connection with gynecological cancer trials. There, international mentors, doctors, research shared experiences from around the Europe. Medicine, including the field of oncogynecology, has not stopped, its is progressing and advancing by the day and hours, that’s why its important to rely on research in this direction and master the skills. DINA KURDIANI, MD, PhD, Tbilisi, Georgia

 We are pleased that all three CEEGOG representatives — DINA KURDIANI, MIHAI STANCA and OLHA KHOPTIANA (Kyiv, Ukraine) — enjoyed the academy and gained valuable experience for their future work in clinical research.

 

             

 

           

 

The next CEEGOG meeting will be scheduled for May 2025 and held in Prague. At this time, we cannot confirm the exact date, but it will be one of the following dates: 15 MAY, 16 MAY, 22 MAY, 23MAY

Please be so kind and save all those days. We hope to confirm the date of the annual CEEGOG meeting by the end of this year.  

We are pleased to inform you that recently an article summarizing the final results of the CEEGOG ox-01/HE4-FU-OVCA study has been published. The CEEGOG ox-01/HE4-FU-OVCA study was the first CEEGOG study to be proposed and approved, focusing on the role of the HE4 marker in the follow-up of advanced ovarian, fallopian tube, and primary peritoneal cancer. The article was published in the Cancers journal,  and for your reference, is to be found in the CEEGOG Members´ shared area. Once again, we sincerely thank all participating sites for their valuable cooperation in the CEEGOG ox-01 study. It was a great pleasure for us to work with each of you!

The first GCIG Cervical Cancer Consensus Conference which focused on Clinical Research  was held in Dublin in Mid-October 2024. Dr. Zoltán Novák (Hungarian National Oncological Institute, Hungary) and Professor David Cibula (General University Hospital in Prague, the Czech Republic) represented CEEGOG there. The topics for discussions have been divided in four groups, i.e. Diagnosis and Staging, Early Cervical Cancer, Locally Advanced Cervical Cancer and Metastatic and Recurrent Disease. The main points of the consensus conference have been summarised in the statements to be published.

  1. ENGOT meeting in Amsterdam, September 26 – 27, 2024
  2. New CEEGOG leadership and members of the CEEGOG Scientific committee, JUNE 2024
  3. Annual CEEGOG mtg in Prague on JUNE 14-15, 2024
  4. CEEGOG meeting in BARCELONA at ESGO congress 2024
  5. Separation of Polish centers from the CEEGOG group
  6. CEEGOG meeting in Istanbul at ESGO congress
  7. Annual CEEGOG mtg in Prague on December 8, 2023
  8. GCIG SPRING meeting in Chicago, May 31 – June 1, 2023
  9. ENGOT Advisory Board, April 2023
  10. ENGOT mtg in Milano, March 9 – 10, 2023